Focus: Ferring Pharmaceuticals is a 5,000+ employee specialty pharmaceutical manufacturer headquartered in Buenos Aires, focused on small molecule manufacturing with a concentrated portfolio in GI and specialty care. The company operates as an established player with peak-stage products generating $36M in annual Part D spending.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Hot — 156 jobs added in 30d
Net +59 (156 new, 97 removed). Aggressive expansion phase.
2 recent layoff filings (12 mo) — 128 affected
Source: state DOL filings via Big Local News
Best fit for Commercial and Regulatory Affairs professionals seeking stability in an established specialty player; higher risk for R&D roles given modest pipeline momentum and recent organizational turbulence.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product representing 91% of company revenue; provides long runway to 2038 but creates dangerous portfolio concentration.
Help build intelligence for Ferring Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ferring Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary peak-stage product with near-term LOE exposure approaching 2030; modest revenue contribution indicates limited diversification.
Tertiary peak-stage asset with extended patent protection through 2032 but minimal revenue impact.
Post-exclusivity generic formulation with minimal revenue contribution; signals mature market presence.
Biologics asset approaching LOE with negligible revenue; indicates limited competitive advantage in growth hormone space.
Minimal revenue contributor nearing end-of-life; demonstrates weak market position in reproductive health despite pipeline emphasis.
Formulation variant of generic desmopressin with no quantified revenue; represents incremental innovation with limited market traction.
Indication-specific desmopressin variant in mature market; contributes minimally to overall portfolio value.
Niche infertility device-drug combination nearing patent cliff; aligns with company's fertility portfolio emphasis but lacks significant commercial traction.
Pipeline candidate under development for nocturnal enuresis; overlaps with NOCDURNA territory and represents potential internal cannibalization risk.
24 discontinued, 9 duplicate formulations not shown
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences Yahoo Finance
Expanding Access to Advanced Care, Biotechnology - Mexico Business News
Expanding Access to Advanced Care, Biotechnology Mexico Business News
8-K Filing: RELMADA THERAPEUTICS, INC. (RLMD) (CIK 0001553643) — PRESS RELEASE ISSUED ON JULY 28, 2026
PRESS RELEASE ISSUED ON JULY 28, 2026
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide - Fierce Pharma
Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide Fierce Pharma
Cosette Pharmaceuticals Names Former Ferring Executive David Bell Chief Commercial Officer - citybiz
Cosette Pharmaceuticals Names Former Ferring Executive David Bell Chief Commercial Officer citybiz
Ferring Pharmaceuticals Expands in Parsippany with FDA-Approved Manufacturing Hub - Parsippany Focus
Ferring Pharmaceuticals Expands in Parsippany with FDA-Approved Manufacturing Hub Parsippany Focus
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Investigating the journey and experience of male patients through infertility clinics.
Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.
+1 more products
Recent layoffs are a major red flag; organization is undergoing transition, suggesting potential further workforce adjustments as pipeline programs mature or underperform.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo